303 related articles for article (PubMed ID: 26541363)
1. Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.
Arora M; Cutler CS; Jagasia MH; Pidala J; Chai X; Martin PJ; Flowers ME; Inamoto Y; Chen GL; Wood WA; Khera N; Palmer J; Duong H; Arai S; Mayer S; Pusic I; Lee SJ
Biol Blood Marrow Transplant; 2016 Mar; 22(3):449-55. PubMed ID: 26541363
[TBL] [Abstract][Full Text] [Related]
2. Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.
Omer AK; Weisdorf DJ; Lazaryan A; Shanley R; Blazar BR; MacMillan ML; Brunstein C; Bejanyan N; Arora M
Biol Blood Marrow Transplant; 2016 May; 22(5):879-83. PubMed ID: 26743342
[TBL] [Abstract][Full Text] [Related]
3. Risk Factors for Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Matched Sibling Donors.
Lazaryan A; Weisdorf DJ; DeFor T; Brunstein CG; MacMillan ML; Bejanyan N; Holtan S; Blazar BR; Wagner JE; Arora M
Biol Blood Marrow Transplant; 2016 Jan; 22(1):134-40. PubMed ID: 26365153
[TBL] [Abstract][Full Text] [Related]
4. Lung transplantation for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation: a single-center experience.
Vogl UM; Nagayama K; Bojic M; Hoda MA; Klepetko W; Jaksch P; Dekan S; Siersch V; Mitterbauer M; Schellongowski P; Greinix HT; Petkov V; Schulenburg A; Kalhs P; Rabitsch W
Transplantation; 2013 Feb; 95(4):623-8. PubMed ID: 23274967
[TBL] [Abstract][Full Text] [Related]
5. Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria.
Cuvelier GDE; Nemecek ER; Wahlstrom JT; Kitko CL; Lewis VA; Schechter T; Jacobsohn DA; Harris AC; Pulsipher MA; Bittencourt H; Choi SW; Caywood EH; Kasow KA; Bhatia M; Oshrine BR; Flower A; Chaudhury S; Coulter D; Chewning JH; Joyce M; Savaşan S; Pawlowska AB; Megason GC; Mitchell D; Cheerva AC; Lawitschka A; West LJ; Pan B; Al Hamarneh YN; Halevy A; Schultz KR
Blood; 2019 Jul; 134(3):304-316. PubMed ID: 31043425
[TBL] [Abstract][Full Text] [Related]
6. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning.
Weisdorf D; Zhang MJ; Arora M; Horowitz MM; Rizzo JD; Eapen M
Biol Blood Marrow Transplant; 2012 Nov; 18(11):1727-33. PubMed ID: 22766220
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Individual versus Composite Endpoints of Acute Graft-versus-Host Disease in Determining Long-Term Survival after Allogeneic Transplantation.
Magenau J; Braun T; Gatza E; Churay T; Mazzoli A; Chappell G; Brisson J; Runaas L; Anand S; Ghosh M; Riwes M; Pawarode A; Yanik G; Reddy P; Choi SW
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1682-1688. PubMed ID: 30710686
[TBL] [Abstract][Full Text] [Related]
8. Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancy.
Lee CJ; Wang T; Chen K; Arora M; Brazauskas R; Spellman SR; Kitko C; MacMillan ML; Pidala JA; Badawy SM; Bhatt N; Bhatt VR; DeFilipp Z; Diaz MA; Farhadfar N; Gadalla S; Hashmi S; Hematti P; Hossain NM; Inamoto Y; Lekakis LJ; Sharma A; Solomon S; Lee SJ; Couriel DR
Transplant Cell Ther; 2024 Jan; 30(1):97.e1-97.e14. PubMed ID: 37844687
[TBL] [Abstract][Full Text] [Related]
9. Late-Onset Acute and Chronic Graft-versus-Host Disease in Children: Clinical Features and Response to Therapy.
Takahashi T; Arora M; Okoev G; DeFor TE; Weisdorf DJ; MacMillan ML
Transplant Cell Ther; 2021 Aug; 27(8):667.e1-667.e5. PubMed ID: 34077812
[TBL] [Abstract][Full Text] [Related]
10. Characterization of Late Acute and Chronic Graft-Versus-Host Disease according to the 2014 National Institutes of Health Consensus Criteria in Japanese Patients.
Ito R; Inamoto Y; Inoue Y; Ito A; Tanaka T; Fuji S; Okinaka K; Kurosawa S; Kim SW; Yamashita T; Fukuda T
Biol Blood Marrow Transplant; 2019 Feb; 25(2):293-300. PubMed ID: 30244104
[TBL] [Abstract][Full Text] [Related]
11. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
[TBL] [Abstract][Full Text] [Related]
12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
13. Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT).
Efebera YA; Geyer S; Andritsos L; Vasu S; Jaglowski S; Bingman A; Blum W; Klisovic R; Hofmeister CC; Benson DM; Penza S; Elder P; Cortright K; Kitzler R; Coombes K; O'Donnell L; Daneault B; Bradbury H; Zhang J; Chen X; Garman S; Ranganathan P; Yu X; Hofstetter J; Yu J; Garzon R; Scrape SR; Lozanski G; Devine SM
Biol Blood Marrow Transplant; 2016 Jan; 22(1):71-9. PubMed ID: 26256940
[TBL] [Abstract][Full Text] [Related]
14. Extracorporeal photophoresis: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
[TBL] [Abstract][Full Text] [Related]
15. Presalvage International Staging System Stage and Other Important Outcome Associations in CD34
Bryant AR; Hilden P; Giralt S; Chung DJ; Maloy M; Landau H; Landgren O; Scordo M; Shah G; Smith EL; O'Reilly RJ; Perales MA; Koehne G
Biol Blood Marrow Transplant; 2020 Jan; 26(1):58-65. PubMed ID: 31493537
[TBL] [Abstract][Full Text] [Related]
16. Day 4 collection of granulocyte colony-stimulating factor-mobilized HLA-matched sibling donor peripheral blood allografts demonstrates no long-term increase in chronic graft-versus-host disease or relapse rates.
Booth G; Yu Y; Harlan RP; Jacoby CE; Tomic KM; Slater SE; Allen BE; Berklich EM; Knight RJ; Dela Cruz J; Fu R; Gandhi A; Cook RJ; Meyers G; Maziarz RT; Newell LF
Cytotherapy; 2023 Apr; 25(4):423-431. PubMed ID: 36690537
[TBL] [Abstract][Full Text] [Related]
17. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
[TBL] [Abstract][Full Text] [Related]
18. Late Gastrointestinal Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Adults.
Sung AD; Hassan S; Cardona DM; Wild D; Nichols KR; Mehdikhani H; Balmadrid B; Detweiler CJ; Shealy M; Cirrincione C; Li Z; Poleski M; Dalton TE; Siamakpour-Reihani S; Chao NJ; Sullivan KM
Biol Blood Marrow Transplant; 2018 Apr; 24(4):734-740. PubMed ID: 29246821
[TBL] [Abstract][Full Text] [Related]
19. CD19(+)CD21(low) B cells and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans syndrome.
Kuzmina Z; Krenn K; Petkov V; Körmöczi U; Weigl R; Rottal A; Kalhs P; Mitterbauer M; Ponhold L; Dekan G; Greinix HT; Pickl WF
Blood; 2013 Mar; 121(10):1886-95. PubMed ID: 23303823
[TBL] [Abstract][Full Text] [Related]
20. Ex Vivo CD34
Barba P; Hilden P; Devlin SM; Maloy M; Dierov D; Nieves J; Garrett MD; Sogani J; Cho C; Barker JN; Kernan NA; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Prockop S; Sauter C; Tamari R; van den Brink MR; Avecilla ST; Meagher R; O'Reilly RJ; Goldberg JD; Young JW; Giralt S; Perales MA; Ponce DM
Biol Blood Marrow Transplant; 2017 Mar; 23(3):452-458. PubMed ID: 28017734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
